COMMUNIQUÉ DE PRESSE
News
-
-
-
-
COMMUNIQUÉ DE PRESSE
Telomir Pharmaceuticals to Participate in BIO 2025 in Boston as Company Prepares for IND Submission and Advances Breakthrough Longevity Platform
Telomir Pharmaceuticals, Inc. to meet prospective partners at BIO International Convention 2025 to accelerate IND submission for Telomir-1, preparing for human dosing in 2026 -
-
-
COMMUNIQUÉ DE PRESSE
Telomir Pharmaceuticals Confirms Telomir-1 Restores Vision and Retinal Structure in Age-Related Macular Degeneration (AMD) Animal Model Using FDA-Recognized Surrogate Endpoints
Telomir Pharmaceuticals reports positive preclinical results for oral drug Telomir-1 in age-related macular degeneration (AMD) model, showing vision restoration, retinal regeneration, and reduced oxidative stress -
-
-
COMMUNIQUÉ DE PRESSE
Telomir Pharmaceuticals Adds Telomir-Ag2 as a Novel Drug Candidate to Pipeline Following Breakthrough Efficacy Against MARSA and Drug-Resistant Infections, Targeting a $30B+ Antimicrobial Market Opportunity
Telomir Pharmaceuticals, Inc. announces Telomir-Ag2, a novel drug candidate addressing antimicrobial resistance with broad-spectrum activity, particularly against drug-resistant pathogens
